Nanoparticles as carriers for the delivery of bevacizumab

Autor:	Luis-de-Redín-Subirá, I. (Inés), Irache, J.M. (Juan Manuel), Agüeros, M. (Maite)
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	genetic structures Farmacia::Farmacia y farmacología [Materias Investigacion] sense organs Ciencias tecnológicas Ciencias médicas eye diseases Evaluación de fármacos Diseño síntesis y estudio de nuevos fármacos
Zdroj:	Dadun. Depósito Académico Digital de la Universidad de Navarra instname
Popis:	Bevacizumab is a humanized monoclonal antibody that targets VEGF and its receptors to inhibit angiogenesis. It has been used in the treatment of several cancers, including breast cancer, metastatic non-small cell lung cancer and colorectal cancer (CRC), and off-label in the treatment of ocular pathologies that present neovascularization as diabetic retinopathy and age-related macular degeneration and corneal neovascularization. Although anti-angiogenic therapies, such as bevacizumab, have improved the clinical outcomes in cancer, their efficacy is limited due to the non-specific biodistribution and low tumor penetration. This results in high doses that can lead to undesirable side effects. Also, the use of bevacizumab in the treatment of corneal neovascularization as eye drops yields low bioavailability (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c49e3b38accea15ff257498b3da9073d https://hdl.handle.net/10171/56361 Zobrazit plný text záznamu